Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.

Cheng Ean CheeJasmeet Singh KharaJohn CheongJek FongSivabalan SivanesanJian Yi ChoyMeibo HuAmrita ViswambaramHan Chong Toh

Published in: Expert review of pharmacoeconomics & outcomes research (2024)

At a WTP threshold of Singapore's GDP/capita, atezolizumab plus bevacizumab is cost-effective compared with sorafenib.

Keyphrases